BioSpace News Archive

Avid Bioservices, Inc. (NASDAQ:CDMO) today announced preliminary earnings estimates for the third quarter and nine months ended January 31, 2024.

Avid Bioservices, Inc. announced that it intends to offer, subject to market conditions and other factors, $160 million aggregate principal amount of Convertible Senior Notes due 2029 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Section 4 of the Securities Act of 1933, as amended.

Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2023.

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2023 on Wednesday, March 13th after market hours.

Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the third quarter ended January 31, 2024, on Tuesday, March 12, 2024, after market close.

Rapid Micro Biosystems, Inc. announced that, effective March 4, 2024, the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase 150,000 shares of the Company’s Class A common stock and 75,000 restricted stock units to a new employee under the Company’s 2023 Inducement Plan, as amended.

Innate Pharma SA announced that an abstract regarding its preclinical asset IPH45, a novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate targeting Nectin-4, has been selected for oral presentation at the American Association for Cancer Research Annual Meeting 2024, taking place April 5-10 in San Diego, California.

Innate Pharma SA announced the first patient was dosed in its Phase 1/2 multicenter trial, investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin’s Lymphoma.

GenSight Biologics announced that recent prospective real-world data from early access programs confirm the benefit of LUMEVOQ® in patients with Leber Hereditary Optic Neuropathy from the ND4 mutation, as observed in clinical trials.

Seattle Children’s Research Institute, the research division of Seattle Children’s Hospital and renowned global leader in pediatric research, and Genezen, a leading gene and cell therapy contract development and manufacturing organization, have unveiled a strategic manufacturing partnership for Seattle Children’s Research Institute’s X-linked agammaglobulinemia program.